Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting Î’2 agonists

van der Woude, H. J.; Winter, T. H.; Aalbers, R.
July 2001
Thorax;Jul2001, Vol. 56 Issue 7, p529
Academic Journal
Background-In vitro the long acting β2, agonist salmeterol can, in contrast to formoterol, behave as a partial agonist and become a partial antagonist to other β2 agonists. To study this in vivo, the bronchodilating effect of salbutamol was measured during methacholine induced moderate to severe bronchoconstriction in patients receiving maintenance treatment with high dose long acting β2 agonists. Methods-A randomised double blind crossover study was performed in 19 asthmatic patients with mean forced expiratory volume in one second (FEV1) of 88.4% predicted and median concentration of methacholine provoking a fall in FEY1 of 20% or more (PC20) of 0.62 mg/ml at entry. One hour after the last dose of 2 weeks of treatment with formoterol (24 μg twice daily by Turbuhaler), salmeterol (100 μg twice daily by Diskhaler), or placebo a methacholine provocation test was performed and continued until there was at least a 30% decrease in FEY1. Salbutamol (50 μg) was administered immediately thereafter, followed by ipratropium bromide (40 μg) after a further 30 minutes. Lung function was monitored for 1 hour after provocation. Results-There was a significant bronchodilating and bronchoprotective effect after 2 weeks of active treatment. The dose of methacholine needed to provoke a fall in FEV1 of ⩾30% was higher after pre-treatment with formoterol (2.48 mg) than with salmeterol (1.58 mg) or placebo (0.74 mg). The difference between formoterol and salmeterol was statistically significant: 0.7 doubling dose steps (95% CI 0.1 to 1.2, p=0.016). The immediate bronchodilating effect of subsequently administered salbutamol was significantly impaired after pretreatment with both drugs (p<0.0003 for both). Three minutes after inhaling salbutamol the increase in FEV1 relative to the pre-methacholine baseline was 15.8%, 7.3%, and 5.5% for placebo, formoterol and salmeterol, respectively (equivalent to increases of 26%, 14%, and 12%, respectively, from the lowest FEV1 after methacholine). At 30 minutes significant differences remained, but 1 hour after completing the methacholine challenge FEV1 had returned to baseline values in all three treatment groups. Conclusion--Formoterol has a greater intrinsic activity than salmeterol as a bronchoprotective agent, indicating that salmeterol is a partial agonist compared with formoterol in contracted human air-ways in vivo. Irrespective of this, prior long term treatment with both long acting β2 agonists reduced the bronchodilating effect of an additional single dose of salbutamol equally, indicating that the development of tolerance or high receptor occupancy overshadowed any possible partial antagonistic activity of salmeterol. Patients on regular treatment with long acting β2, agonists should be made aware that an additional single dose of a short acting β2, agonist may become less effective.


Related Articles

  • MDI WITH SPACER VS NEBULIZER IN PEDIATRIC ASTHMA. Shaughnessy, Allen F.; Slawson, David C. // Journal of Family Practice;Jan1996, Vol. 42 Issue 1, p29 

    This article compares the effectiveness of the administration of beta-agonist by a metered-dose inhaler with a spacer to that of administration with a nebulizer. Nebulized beta-agonist therapy has been the standard of care for patients with acute asthma exacerbations. Several studies in adults,...

  • Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma. O'byrrie, P. M.; Bisgaard, H.; Godard, P. P. // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p116 

    The article presents a study on the effectiveness of budesonide plus formoterol (BUD+FORM) for severe exacerbations in asthma. Researchers found that time to first severe exacerbation was greater in the BUD+FORM for both group than in the BUD+FORM plus SABA group or BUD plus SABA group....

  • Developing robust formoterol-containing suspension pMDls with enhanced shelf lives. Slowey, Alex; Righton, Louise; Bainbridge, Paul // Pharmaceutical Technology Europe;Oct2009, Vol. 21 Issue 10, p54 

    The article focuses on the result of the study on the development of robust formoterol-containing pressurized metered-dose inhaler (pMDI) systems. It states that formoterol will be a characteristic of the asthma and chronic obstructive pulmonary disease (COPD) market, which is used together with...

  • A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease. Sovani, Milind P; Whale, Christopher I.; Tattersfield, Anne. E // Drug Safety;2004, Vol. 27 Issue 10, p689 

    The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease...

  • Arformoterol: (R,R)-Eformoterol, (R,R)-Formoterol, Arformoterol Tartrate, Eformoterol-Sepracor, Formoterol-Sepracor, R,R-Eformoterol, R,R-Formoterol. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 1, p25 

    Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the β[sub 2]-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor...

  • Budesonide/Formoterol: A Viewpoint by Paul W. Jones. Jones, Paul W. // Drugs;2004, Vol. 64 Issue 4, p444 

    Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and formoterol, a long-acting J32-agonist, inhaled as a dry powder. Current guidelines for chronic obstructive pulmonary disease (COPD) recommend a long-acting p2-agonist for patients whose symptoms are not...

  • Budesonide/Formoterol: A Viewpoint by Michael Roth1,2. Michael Roth, Paul W. // Drugs;2004, Vol. 64 Issue 4, p443 

    This article presents views of the author on formoterol. Corticosteroids combined with long-acting J32-agonists, for example budesonide/formoterol, have been suggested for the treatment of inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...

  • Budesonide/formoterol may be used for adjustable maintenance dosing in asthma. Simcock, D. // Thorax;Jun2004, Vol. 59 Issue 6, p476 

    This randomized, double blind/open two phase multicentre study, sponsored by Astra Zeneca, was conducted over 7 months to find out if asthma control was better when patients adjusted the maintenance dose of inhaled budesonide/formoterol according to asthma symptoms than when fixed dose (FD)...

  • Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: Randomized controlled trial comparing once- and twice-daily dosing in patients with asthma. Berger, William E.; Bleecker, Eugene R.; O'Dowd, Liza; Miller, Christopher J.; Mezzanotte, William // Allergy & Asthma Proceedings;Jan/Feb2010, Vol. 31 Issue 1, p49 

    Asthma guidelines recommend titrating maintenance medications to the lowest effective dose. This study assessed the efficacy and tolerability of reducing the frequency of dosing in patients previously controlled with twice-daily budesonide/formoterol (BUD/FM) pressurized metered-dose inhaler...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics